Abstract 317P
Background
Molecular characteristics are essential for the classification and grading of glioma. However, the majority of current understanding is based on public databases that might not accurately reflect the Asian population. Here, we studied the genetic landscape of Chinese glioma patients in hope to provide strong rationales for future molecular classification and prognosis of glioma.
Methods
Tissue samples from 81 glioma patients of which 21 (26%) were astrocytoma (A) and oligodendroglioma (O), 16 (20%) were anaplastic astrocytoma/oligodendroglioma (AO/AA), 32 (40%) were Glioblastoma (GBM), and 8 (10%) were diffuse midline glioma underwent next-generation sequencing with Acornmed panel including 808 cancer-relevant genes.
Results
We identified currently established molecular pathologic markers of glioma, including TP53 (41%),TERT (34%), IDH1/2 (30%), PTEN (19%), ATRX (18%), EGFR (16%), H3F3A (10%) and BRAF (6%). IDH mutations were frequent in A and O and were a major discriminate of biologic class (P=0.002). IDH-mutant A/O (grades II) were characterized by MGMT methylation, ATRX, and CIC mutations. AO/AA (grades III) were also IDH1/2-mutant, but instead are characterized by TP53, BRAF, and FUBP1 mutations. GBM typically lacked IDH1/2 mutations and demonstrated EGFR, PTEN, TP53, PIK3CA, and CDKN2A alterations, and TERT promoter mutations. Copy number variations as EGFR, PDGFRA, MET, KIT, which were also significantly associated with GBM but not used for clinical classification (P=0.001). Clinically actionable genetic alterations were detected in 80.95%, 81.25%, and 93.75% of A/O, AA/AO, and GBM, respectively.
Conclusions
We demonstrate that genes characterize the distinction between these pathologic subsets. These results further define molecular subsets of gliomas which may potentially be used for patient stratification and suggest potential targets for treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Li, H. Cheng, H. Wang, S. Cao: Full/Part-time employment: Beijing Acornmed Biotechnology Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session